Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2002

View Archived Issues

New compound for toxoplasmosis requires a functional immune system

Nabi discusses development plans for 2002

Beyond Genomics and diaDexus enter cancer diagnostic and drug discovery agreement

Ono-2506 improves outcome in murine models of EAE

Improved antidiabetic and hypolipidemic activity in a series of dual PPARalpha/PPARgamma agonists

Commonly used antibiotic shows potential for Rx of multiple sclerosis

Effects of raloxifene on cardiovascular events analyzed using data from the MORE trial

AnorMED looks forward to progress in 2002

EpiDex to be regulated as a medical device in the U.S.

Preliminary results of transmissible spongiform encephalopathies diagnostic test

sNDA submitted for Prevacid in pediatric patients

Positive results from phase I trial of PT-141 in erectile dysfunction

AGIX-4207 completes phase I in rheumatoid arthritis

ImmunoGen and Millennium sign exclusive product license

Chiron completes cash tender offer for Matrix stock

ML-3000 fails to meet all efficacy endpoints in E.U. trial

Novel anticancer therapy target validated at Cell Therapeutics

Casodex 150 mg receives priority review in early-stage prostate cancer

Sucampo licenses tacrolimus from Fujisawa for ophthalmic use

DuPont scientists synthesize compounds with CRF-antagonist activity

Compounds with myocardial electrophysiological activity claimed by AstraZeneca

Akzo Nobel identifies aminoisoquinoline-containing compounds effective as thrombin inhibitors

Inhibitors of cyclin-dependent kinases with potential as antitumor agents

Taisho compounds show utility in CRF-mediated conditions

Recent patent covers Boehringer Ingelheim compounds useful for the treatment of HCV infection

Scientists at Nikken Chemicals prepare adenosine derivatives with antihyperlipidemic activity

FDA Science Forum to be broadcast by Prous Science

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...